Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer

Journal of Urology

Volumn 155, Issue 1, 1996, Pages 213-219

  Gleave, Martin E ^a   Goldenberg, S Larry ^a   Jones, Edward C ^a   Bruchovsky, Nicholas ^a   Sullivan, Lorne D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Androgens; Biochemistry; Prostatectomy; Prostatic neoplasms

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CYCLINE; CYPROTERONE ACETATE; CYTOKERATIN; DIETHYLSTILBESTROL; FLUTAMIDE; GONADORELIN AGONIST; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ANDROGEN THERAPY; ANTIGEN DETECTION; ARTICLE; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; ORAL DRUG ADMINISTRATION; PELVIS LYMPHADENECTOMY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; TESTOSTERONE BLOOD LEVEL;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; FLUTAMIDE; GONADORELIN; HUMAN; MALE; MIDDLE AGE; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SUPPORT, NON-U.S. GOV'T; TESTOSTERONE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0029656221     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)66598-4     Document Type: Article

References (31)

1. Rosen, M. A., Goldstone, L., Lapin, S., Wheeler, T. and Scardino, P. T.: Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J. Urol., 148: 331, 1992.
2. Lange, P. H. and Narayan, P.: Understaging and undergrading of prostate cancer: argument for postoperative radiation as adjuvant therapy. Urology, 21: 113, 1983.
3. Bigg, S. W., Kavoussi, L. R. and Catalona, W. J.: Role of nerve-sparing radical prostatectomy for clinical stage B2 prostate cancer. J. Urol., 144: 1420, 1990.
4. Anscher, M. S. and Prosnitz, L. R.: Postoperative radiotherapy for patients with carcinoma of the prostate undergoing radical prostatectomy with positive surgical margins, seminal vesicle involvement and/or penetration through the capsule. J. Urol., 138: 1407, 1987.
5. Jones, E. C.: Resection margin status in radical retropubic prostatectomy specimens: relationship to type of operation, tumor size, tumor grade and local tumor extension. J. Urol., 144: 89, 1990.
6. Bosch, R. J., Kurth, K. H. and Schroeder, F. H.: Surgical treatment of locally advanced (T3) prostatic carcinoma: early results. J. Urol., 138: 816, 1987.
7. Trapasso, J. G., deKernion, J, B., Smith, R. B. and Dorey, F.: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J. Urol., part 2, 152: 1821, 1994.
8. Schellhammer, P. F.: Radical prostatectomy: patterns of local failure and survival in 67 patients. Urology, 31: 191, 1988.
9. Lange, P. H., Ercole, C. J. and Vessella, R. L.: Serum prostatic specific antigen (PSA) in the management of patients after radical prostatectomy (RP). J. Urol., part 2, 139: 314A, abstract 607, 1988.
10. Frazier, H. A., Robertson, J. E., Humphrey, P. A. and Paulson, D. F.: Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urol., 149: 516, 1993.
11. Oesterling, J. E.: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol., 145: 907, 1991.
12. Schulman, C. C.: Neoadjuvant androgen blockade prior to prostatectomy: a retrospective study and critical review. Prostate, suppl., 5: 9, 1994.
13. Fair, W. R., Aprikian, A., Sogani, P., Reuter, V. and Whitmore, W. F., Jr.: The role of neoadjuvant hormonal manipulation in localized prostatic cancer. Cancer, suppl., 71: 1031, 1993.
14. Labrie, F., Dupont, A., Cusan, L., Gomez, J. L., Diamond, P., Koutsilieris, M., Suburu, R., Fradet, Y., Lemay, M. and Tetu, B.: Downstaging of localized prostate cancer by neoadjuvant therapy with flutanide and lupron: the first controlled and randomized trial. Clin. Invest. Med., 16: 499, 1993.
15. Gleave, M. E., Hsieh, J. T., Wu, H. C., von Eschenbach, A. C. and Chung, L. W.: Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res., 52: 1598, 1992.
16. Miller, J. I., Ahmann, F. R., Drach, G. W., Emerson, S. S. and Bottaccini, M. R.: The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J. Urol., part 2, 147: 956, 1992.
17. Goldenberg, S. L., Bruchovsky, N., Gleave, M. E., Sullivan, L. D. and Akakura, K.: Intermittent androgen suppression in the treatment of prostate cancer: preliminary report. Urology, 45: 839, 1995.
18. Goldenberg, S. L. and Bruchovsky, N.: Use of cyproterone acetate in prostate cancer. Urol. Clin. N. Amer., 18: 111, 1991.
19. Stephenson, R. A. and Middleton, R. G.: Radical retropubic prostatectomy using wide excision (non-nerve sparing) or nerve sparing techniques; improved cancer control vs. potency preservation. In: Medical and Surgical Management of Prostate Cancer. Edited by R. G. Middleton. New York: Igaku-Shoin Medical Publishers, in press.
20. Vessella, R. L., Noteboom, J. and Lange, P. H.: Evaluation of the Abbott IMx automated immunoassay of prostate-specific antigen. Clin. Chem., 38: 2044, 1992.
21. Huggins, C. and Hodges, C. V.: Studies on prostatic cancer; effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 1: 293, 1941.
22. Bruchovsky, N.: The metabolism of testosterone and dihydrotestosterone in an androgen-dependent tumour. A possible correlation between dihydrotestosterone and tumor growth in vivo. Biochem. J., 127: 561, 1972.
23. Bruchovsky, N., Rennie, P. S., Coldman, A. J., Goldenberg, S. L., To, M. and Lawson, D.: Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res., 50:2275, 1990.
24. van Weerden, W. M., van Kreuningen, A., Elissen, N. M., Vermeij, M., de Jong, F. H., van Steenbrugge, G. J. and Schröder, F. H.: Castration-induced changes in morphology, androgen levels, and proliferation activity of human prostate cancer tissue grown in athymic nude mice. Prostate, 23: 149, 1993.
25. Kerr, J. F., Winterford, C. M. and Harmon, B. V.: Apoptosis. Its significance in cancer and cancer therapy. Cancer, 73: 2013, 1994.
26. Buttyan, R., Olsson, C. A., Pintar, J., Chang, C., Bandyk, M., Ng, P. Y. and Sawczuk, I. S.: Induction of the TRPM-2 gene in cells undergoing programmed death. Mol. Cell. Biol., 9: 3473, 1989.
27. Macfarlane, M. T., Abi-aad, A., Stein, A., Danella, J., Belldegrun, A. and deKernion, J. B.: Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer. J. Urol., 150: 132, 1993.
28. Oesterling, J. E., Andrews, P. E., Suman, V. J., Zincke, H. and Myers, R. P.: Preoperative androgen deprivation therapy: artificial lowering of serum prostate specific antigen without downstaging the tumor. J. Urol., 149: 779, 1993.
29. Goldenberg, S. L., Klotz, L. H., Jewett, M. A. S., Srigley, J., Barkin, J., Mador, D., Fradet, Y., Chin, J. L., Paquin, J.-M., Laplante, S. and the Canadian Urologic Oncology Group: Randomized, controlled study of neoadjuvant reversible androgen withdrawal therapy with cyproterone acetate in the surgical management of localized prostate cancer. J. Urol., part 2, 153: 254A, abstract 103, 1995.
30. Stamey, T. A., Kabalin, J. N., Ferrari, M. and Yang, N.: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. J. Urol., 141: 1088, 1989.
31. Lin, M. F., Garcia-Arenas, R., Kawachi, M. and Lin, F. F.: Regulation of the expression of prostatic acid phosphatase in LNCaP human prostate carcinoma cells. Cell. Molec. Biol. Res., 39: 739, 1993.